Onkologie. 2017:11(3):121-126 | DOI: 10.36290/xon.2017.024

Hodgkin lymphoma in elderly patients

Heidi Móciková1, Alice Sýkorová2, Jana Marková1
1Interní hematologická klinika FN Královské Vinohrady a 3. lékařská fakulta Univerzity Karlovy v Praze, 2IV. interní hematologická klinika FN Hradec Králové a Lékařská fakulta Univerzity Karlovy v Hradci Králové

Hodgkin lymphoma (HL) is a curable cancer in 80 % up to 90 % of younger patients but prognosis in elderly patients over 60 years

is considerably worse. Elderly patients represent 10–20 % of all HL cases. Due to the worse performance status and various comorbidities

in elderly patients their tolerance of chemotherapy is significantly lower when compared to younger patients. Based on

the data from published literature as well as data from the Czech Registry of HL patients this article summarizes recommended

treatment, possible toxicity and outcome of elderly patients with HL. Currently new drugs alone or in combination with chemotherapy

are tested in order to improve efficacy and to reduce adverse events of treatment.

Keywords: Hodgkin lymphoma, elderly patients, chemotherapy, radiotherapy

Published: June 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Móciková H, Sýkorová A, Marková J. Hodgkin lymphoma in elderly patients. Onkologie. 2017;11(3):121-126. doi: 10.36290/xon.2017.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pulte D, Jansen L, Gondos A, et al. GEKID Cancer Survival Working Group. Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. Br J Haematol 2014; 164: 851-817. Go to original source... Go to PubMed...
    2. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23: 5052-5060. Go to original source... Go to PubMed...
    3. Böll B, Bredenfeld H, Görgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011; 118: 6292-6298. Go to original source... Go to PubMed...
    4. Halbsguth TV, Nogova L, Mueller H, et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2010; 116: 2026-2032. Go to original source... Go to PubMed...
    5. Proctor SJ, Wilkinson J, Jones G, et al. Prospective evaluation of treatment outcome in 175 patients with Hodgkin Lymphoma (HL) aged sixty years or over: the SHIELD Study. Blood 2012; 119: 6005-6015. Go to original source... Go to PubMed...
    6. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. B J Haematol 2013; 161: 76-86. Go to original source... Go to PubMed...
    7. Halbsguth TV, Böll B, Borchmann P, et al. The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep 2011; 6: 164-171. Go to original source... Go to PubMed...
    8. Björkholm M, Svedmyr E, Sjöberg J, et al. How we treat elderly patients with Hodgkin lymphoma. Curr Opin Oncol 2011; 23: 421-428. Go to original source... Go to PubMed...
    9. Böll B, Goergen H, Arndt N, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol 2013; 31: 4431-4437. Go to original source... Go to PubMed...
    10. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005; 129: 597-606. Go to original source... Go to PubMed...
    11. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012; 119: 692-695. Go to original source... Go to PubMed...
    12. Engert A, PlütschowA, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652. Go to original source... Go to PubMed...
    13. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015; 385: 1418-1427. Go to original source... Go to PubMed...
    14. Böll B, Görgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 Trials. J Clin Oncol 2013; 31: 1522-1529. Go to original source... Go to PubMed...
    15. Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127: 2189-2192. Go to original source... Go to PubMed...
    16. Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014; 89: 854-862. Go to original source... Go to PubMed...
    17. Dědečková K, Mociková H, Marková J, et al. Proton radiotherapy for mediastinal Hodgkin lymphoma: single institution experience. Haematologica 2016; 101 (s5). Go to PubMed...
    18. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 2015; 372: 1598-1607. Go to original source... Go to PubMed...
    19. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014; 32: 1188-1194. Go to original source... Go to PubMed...
    20. von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012; 30: 907-913. Go to original source... Go to PubMed...
    21. Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 2016; 374: 2419-2429. Go to original source... Go to PubMed...
    22. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-1799. Go to original source... Go to PubMed...
    23. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Annals of Oncology 2005; 16: 124-131. Go to original source... Go to PubMed...
    24. Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 2007; 48: 570-576. Go to original source... Go to PubMed...
    25. Levis A, Anselmo AP, Ambrosetti A, et al.: VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Annals of Oncology 2004; 15: 123-128. Go to original source... Go to PubMed...
    26. Zallio F, Tamiazzo S, Monagheddu C, et al. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol 2016; 172: 879-888. Go to original source... Go to PubMed...
    27. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372(4): 311-319. Go to original source... Go to PubMed...
    28. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016 Jun 27. DOI: http://dx.doi.org/10.1200/JCO.2016.67.3467 [Epub ahead of print]. Go to original source... Go to PubMed...
    29. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821. Go to original source... Go to PubMed...
    30. Younes A, Gopal k, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-2189. Go to original source... Go to PubMed...
    31. Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 2015; 126: 2798-2804. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.